BTK and B-cell chronic lymphocytic leukemia: Furthermore, the second-generation BTK inhibitor acalabrutinib has also been approved by the FDA for treatment of mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma.